Grace Therapeutics Inc. (NASDAQ:GRCE), a $32.85 million market cap biotechnology company whose stock has gained over 37% in the past six months, has announced successful outcomes from its Phase 3 ...
13h
Trial Met the Primary Endpoint and Provides Evidence of GTx-104 Clinical Benefit Compared to Orally Administered NimodipineNew Drug Application ...
Nvidia describes the whole thing using the term 'Inference on Sample,' and the results are impressive, to say the least.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback